Bladder Carcinoma — Trials

Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 141
Recruiting: 74
Ph III recruiting: 14
Growth YoY: +6.5%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 48.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 1–50 of 94 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	recruiting	Phase 2	314	National Cancer Institute (NCI)NIH	2	Sep 29, 2026	clinicaltrials
NCT05987241	Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study	recruiting	Phase 2 / Phase 3	992	National Cancer Institute (NCI)NIH